Chinese official warns of drug-market crackdown; FDA wants more data on new Treanda use;

@FiercePharma: EMA says it's investigating Roche for possible shortcomings in pharmacovigilance. More | Follow @FiercePharma

> China's health minister says the government is reforming hospital procurement and cracking down on cozy relationships between doctors and pharmaceutical companies. Report | Report

> Indian generics maker Lupin says it's on track to launch 15 new generic products in the U.S. by the end of its fiscal year, including 8-10 contraceptives. Report

> FDA asked Teva Pharmaceutical Industries ($TEVA) for more data about its cancer drug Treanda as the agency reviews a new first-line indication for patients with non-Hodgkin's lymphoma. Report

> Tanzania Pharmaceutical Industries is spending 5 million euros ($6.48 million) on a new plant that will begin production in March, officials said. Report

> FDA has granted $2.7 million to back a study pitting the transplant drug Prograf against generic versions of the drug, to determine whether copies are as effective. Report

Medical Device News

 @FierceMedDev: Roche Dx is slashing jobs as it rethinks its diabetes business. More | Follow @FierceMedDev

 @MarkHFierce: Scientists can produce stem cells in great numbers from cadaver scalp tissue. More | Follow @MarkHFierce

 @DamianFierce: Japan's Sysmex is in talks to buy Dune Medical Devices for $200M, according to a report. More | Follow @DamianFierce

> Allegro celebrates encouraging early data for lung cancer test. Article

> Philips Healthcare soars in Q3. Item

Biotech News

 @FierceBiotech: Hirano bodies may block Alzheimer's-related cell death. More | Follow @FierceBiotech

 @JohnCFierce: So AstraZeneca and Ironwood are getting close. AZ pays $25M in cash, up to $125M in miles for China rights to linaclotide; sharing revenue. | Follow @JohnCFierce

 @RyanMFierce: e-Therapeutics (computer-enabled network pharmacology) has shelved a MRSA candidate to focus on cancer program. More (reg. req.) | Follow @RyanMFierce

> Abbott doubles down on ADC cancer drugs in $245M-plus Seattle Genetics pact. Report

> GSK taps stem cell discovery to spot heart threats early. Story

> Celgene wraps promising PhIII data on new multiple myeloma challenger. Article

Biotech Research News

> Australian scientists grow HIV antibodies in cow's milk. More

> A transplant anti-rejection treatment could be the next cancer drug. Article

> Pluristem's placental stem cells combat fibrosis in preclinical test. Story

> Scientists produced stem cells from cadaver scalp tissue. Item

Pharma Manufacturing News

> China's WuXi AppTec opens biologics plant. More

> Mexico's Neolpharma snags Pfizer Puerto Rico plant. News

> Mylan buying vertically integrated SMS oncology plant. Story

And Finally... Statin therapy may have another benefit--preventing esophageal cancer--according to a new a data analysis. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.